minocycline and Candidiasis--Vulvovaginal

A double-blind, random distribution study showed that a lower than recommended dose of minocycline--50 mg twice daily--was as effective as a dose of 250 mg twice daily of tetracycline for treatment of acne vulgaris in comparable patient groups, and that minocycline produced no vestibular side effects at the lower dosage. Like tetracycline, minocycline did not produce the phototoxicity associated with demeclocycline or the life-threatening colitis associated with clindamycin. Patients in this study did not develop a resistance either to minocycline or to tetracycline. Studies of the use of minocycline in patients who have developed tetracycline resistance and long-range studies of patients on the new lower dose of minocycline are now underway.

Topics: Acne Vulgaris; Adolescent; Adult; Candidiasis, Vulvovaginal; Clinical Trials as Topic; Female; Humans; Male; Minocycline; Tetracycline; Tetracyclines; Time Factors

Two groups of women with non-specific genital infection were treated for two weeks with tetracycline 250 mg six-hourly and minocycline 100 mg twice daily respectively. Cultures for yeasts were performed before treatment and at the end of the first and second weeks. Before treatment yeasts, mostly Candida albicans, were recovered from 13% of the women. After one and two weeks' treatment yeasts were isolated from 22 and 29% of women treated with tetracycline, and from 19 and 29% of women treated with minocycline. It is concluded that despite inhibition of the growth of yeasts shown by minocycline in vitro, there is no evidence of any significant difference between the actions of tetracycline and minocycline on the vaginal yeast flora.

Topics: Candida albicans; Candidiasis, Vulvovaginal; Clinical Trials as Topic; Female; Humans; Minocycline; Tetracycline; Tetracyclines; Vagina; Vaginal Smears; Vulvovaginitis; Yeasts

Topics: Acne Vulgaris; Administration, Oral; Candidiasis, Vulvovaginal; Clindamycin; Colitis; Demeclocycline; Drug Evaluation; Erythromycin; Female; Humans; Minocycline; Photosensitivity Disorders; Tetracycline; Time Factors